MOGAMULIZUMAB

mogamulizumab 20 mg/5 mL injection, 5 mL vial

MOGAMULIZUMAB (15318F)

mogamulizumab 20 mg/5 mL injection, 5 mL vial
15318F
Body System:
Manner of administration:Injection
Public
Chemotherapy Items for Public Hospital use
Authority Required

Restriction

Indication: Cutaneous T-cell lymphoma
Treatment phase: Initial treatment
Quantities & Cost
Max amount # of repeats DPMA Max safety net General Patient Charge
Max amount: 120 mg # of repeats: 3 DPMA: $13,189.23 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
POTELIGEO
(mogamulizumab 20 mg/5 mL injection, 5 mL vial)